| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Filing example | brepocitinib dermatomyositis | NDA | — | Small Molecules | Rare Diseases | ||
NDA Filing example | brepocitinib dermatomyositis | NDA | — | Small Molecules | Rare Diseases | ||
NDA Filing example | brepocitinib dermatomyositis | NDA | — | Small Molecules | Rare Diseases |
Recent Updates
Recently added Catalysts
Roivant Sciences Ltd.$31.43
-0.2 (-0.64%)
C 59Pipeline Score Tools & Services · Commercial
Market Cap
21.55 B
EPS
-0.45
P/E Ratio
-
Value Trade
103.41 M
SEC Financials
Q1 2026Dilution Risk
Revenue
2.52 M
R&D Expenses
198.94 M
Operating CF
-187.59 M
Total Assets
5.71 B
Total Liabilities
416.27 M
Equity
4.53 B
D/E Ratio
12,345
2.46 %
Week
1.46 %
1 Month
9.62 %
3 Month
47.88 %
6 Month
204.16 %
5 Year
185.33 %
All Time
Cash Data
Cash Position
4.29 B
Monthly Burn
62.53 M
Runway
67.6 mo
Burn Trend
SEC Filing
May 20, 2026
Overview
Volume
8.26 M
52 Week Range
10.59 - 32.79
% held by Insiders
28.09 %
% held by Institutions
73.02 %
Enterprise Value
18.13 B
Total Shares
716.25 M
Short %
7.01 %
Float Shares
371.02 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C59
Pipeline Score $3.6B
Pipeline ValueValuation Signal
6
Drugs Scored0.2x
rNPV / MCap Top 88%
Mid Cap (rank 110 of 905)
Percentile RankRoivant Sciences Ltd. carries a moderate pipeline score (59/100), with $4.2B risk-adjusted pipeline value, led by Gimsilumab in COVID-19 (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gimsilumab Small molecule | COVID-19 | Phase 2 | NCT04351243 | 40% | $1.0B | COMPLETED | 227 | - | - | Apr 1, 2021 | - | Dec 14, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
brepocitinib | dermatomyositis,non-infectious uveitis,cutaneous sarcoidosis | Phase 3 | 2025-08-12 | |||
brepocitinib | dermatomyositis,non-infectious uveitis,cutaneous sarcoidosis | Phase 3 | 2025-08-12 | |||
brepocitinib | dermatomyositis,non-infectious uveitis,cutaneous sarcoidosis | Phase 3 | 2025-08-12 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ROIV
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Roivant Sciences Ltd. (ROIV) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
ROIV
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ROIV
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ROIV
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ROIV Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ROIV Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ROIVRoivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
Roivant reported its financial results for the fourth quarter and fiscal year ended March 31, 2026, highlighting promising clinical data for IMVT-1402 in rheumatoid arthritis and brepocitinib's Breakthrough Therapy Designation for cutaneous sarcoidosis. The company anticipates a commercial launch of brepocitinib in dermatomyositis by September 2026 and has a robust cash position of $4.3 billion. However, R&D expenses have increased significantly, reflecting ongoing investments in their pipeline.
Read more →ROIVRoivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
Roivant has announced a live conference call scheduled for May 20, 2026, to report its financial results for the fourth quarter and fiscal year ending March 31, 2026. The call will also provide a business update. Roivant's pipeline includes several innovative therapies targeting various autoimmune conditions and pulmonary hypertension.
Read more →ROIVPriovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
Priovant has launched a new Phase 2b/3 clinical trial for brepocitinib targeting lichen planopilaris (LPP), a severe inflammatory scalp disorder. This trial marks the fourth indication for brepocitinib, which has shown promising results in previous studies. The FDA has granted Priority Review for brepocitinib's NDA for dermatomyositis, with further developments expected in other indications.
Read more →ROIVRoivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
Roivant has launched a new Phase 2b/3 trial for brepocitinib targeting lichen planopilaris (LPP), a severe inflammatory scalp disorder. This marks the fourth indication for brepocitinib, which has shown promising results in prior studies. Meanwhile, Immunovant reported that its Phase 3 studies for batoclimab in thyroid eye disease did not meet their primary endpoint. An investor call is scheduled to discuss these developments.
Read more →ROIVNew England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
Priovant Therapeutics announced positive results from the Phase 3 VALOR trial of brepocitinib for dermatomyositis, published in the New England Journal of Medicine. The trial met its primary endpoint, showing significant improvement in Total Improvement Score and enabling corticosteroid reduction. Despite some increased serious infections, the findings suggest a potential shift in treatment paradigms for dermatomyositis.
Read more →ROIVPriovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
Priovant Therapeutics announced that the FDA has accepted its New Drug Application for brepocitinib, a potential treatment for dermatomyositis, and granted it Priority Review. The application is supported by positive results from the Phase 3 VALOR study, which showed significant improvements in patient outcomes. If approved, brepocitinib would be the first targeted therapy for this condition, with a launch anticipated by September 2026.
Read more →ROIVRoivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
Roivant announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis, marking a significant milestone in treatment options for this condition. The BEACON study demonstrated substantial clinical improvements, particularly in the 45 mg dosage group. The company plans to initiate a pivotal Phase 3 study in 2026, further advancing its pipeline.
Read more →ROIVPriovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
Priovant Therapeutics announced positive Phase 2 results for brepocitinib in treating cutaneous sarcoidosis, marking a significant advancement in a field lacking approved therapies. The BEACON study demonstrated meaningful clinical improvements in patients compared to placebo, with high response rates and a favorable safety profile. The company plans to initiate a Phase 3 program in 2026.
Read more →ROIVRoivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
Roivant has announced a live conference call scheduled for February 6, 2026, to discuss its financial results for the second quarter ended December 31, 2026, along with a business update. The company is focused on advancing its pipeline of therapies, including treatments for autoimmune conditions and pulmonary hypertension. The call will be accessible via phone and webcast, with archived details available on their website.
Read more →ROIVRoivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day
Roivant hosted an Investor Day in New York City, highlighting its pipeline progress and strategic outlook. CEO Matt Gline emphasized the potential of three major products, including brepocitinib for dermatomyositis, which is set for a Phase 3 readout. The company aims for significant commercial launches in the coming years.
Read more →ROIVRoivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
Roivant reported its financial results for Q2 2025, highlighting a cash position of $4.4 billion. The company noted transformative data from brepocitinib and promising results from Immunovant in Graves' disease. However, it also reported a loss from continuing operations of $166 million, reflecting increased R&D expenses. Roivant plans to provide further updates at an investor day in December.
Read more →ROIVRoivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
Roivant and Priovant Therapeutics announced positive results from the Phase 3 VALOR study of brepocitinib for dermatomyositis. The study demonstrated significant improvements in the primary endpoint, with brepocitinib showing a mean Total Improvement Score of 46.5 compared to 31.2 for placebo. This marks a groundbreaking achievement in the treatment of dermatomyositis, with plans for an NDA submission in 2026.
Read more →ROIVRoivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List
Roivant has been recognized as one of the Best Workplaces in BioPharma by Fortune and Great Place To Work, ranking 28th in the small & medium category. This marks Roivant's first appearance on the list, highlighting its commitment to a positive workplace culture. The selection was based on survey responses from nearly 40,000 employees across the biotechnology and pharmaceutical sectors.
Read more →ROIVRoivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
Immunovant, Inc. presented promising six-month off-treatment data for batoclimab in uncontrolled Graves' disease patients. The results indicate significant remission rates and potential disease modification. The findings will be discussed at the upcoming American Thyroid Association meeting, highlighting the drug's transformative potential for treatment if approved by the FDA.
Read more →ROIVRoivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
Roivant and Priovant Therapeutics will host a live investor video conference on June 17 to discuss brepocitinib and its potential impact on dermatomyositis. Brepocitinib, a dual selective inhibitor, aims to address the unmet medical needs of patients suffering from this condition. The conference will provide insights into the drug's clinical development and therapeutic potential.
Read more →Competitive Position
How ROIV ranks across every disease it competes inCompetitive Position is a premium feature
See how ROIV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial